treatment crohn diseas diberri digest diseas autoimmun diseas genet disord gastroenterolog treatment crohn diseas involv treat acut symptom diseas maintain remiss treatment initi involv medic elimin infect gener antibiot reduc inflamm gener aminosalicyl antiinflammatori drug corticosteroid surgeri requir complic obstruct abscess diseas doe respond drug reason time onc remiss induc goal treatment becom mainten remiss avoid return activ diseas flare becaus sideeffect prolong corticosteroid avoid peopl abl maintain remiss aminosalicyl alon mani requir immunosuppress drug aminosalicyl antiinflammatori drug includ follow mesalazin mesalamin market form asacol pentasa salofalk dipentum rowasa sulfasalazin convert sulfapyridin intestin bacteria sulfapyridin therapeut rheumatoid arthriti howev sulfapyridin compon limit factor treatment crohn diseas becaus high sideeffect profil compound treatment mildtomoder crohn diseas usual consid therapi diseas ileum side colon particularli lower side profil compar corticosteroid corticosteroid antiinflammatori drug steroid enema treatment rectal diseas symptom corticosteroid class antiinflammatori drug primarili treatment moder sever flare crohn diseas sparingli avail treatment sideeffect side corticosteroid includ cush syndrom mania insomnia hypertens high blood glucos osteoporosi avascular necrosi long bone confus anabol steroid enhanc athlet perform commonli prescrib oral steroid prednison typic dose mgkg induct remiss intraven steroid case refractori oral steroid oral steroid administ hospit set becaus corticosteroid reduc abil fight infect care ensur nt activ infect particularli intraabdomin abscess befor initi steroid budesonid oral corticosteroid limit absorpt high level firstpass metabol quantiti steroid enter bloodstream ha treatment mildtomoder crohn diseas mainten remiss crohn diseas formul entocort budesonid releas ileum colon therefor ha topic diseas area budesonid combin antibiot activ crohn diseas steroid enema diseas lower colon rectum order treat symptom hydrocortison budesonid liquid foam enema market reason corticosteroid howev host side veri seriou desir curtail whenev possibl mercaptopurin immunosuppress drug azathioprin immunosuppress mainten therapi crohn diseas purin antimetabolit interfer synthesi purin requir inflammatori cell durat action month unwieldi induct remiss drug dose mgkg literatur support higher dose azathioprin follow indic mainten therapi peopl depend steroid fistul diseas induct remiss steroid refractori diseas mainten remiss surgeri crohn diseas azathioprin howev particularili danger drug great potenti invit host potenti fatal infect list fda human carcinogen infliximab infliximab market remicad mousehuman chimer antibodi target tumour necrosi factor cytokin inflammatori respons administ intraven dose weight infliximab ha util follow mainten remiss peopl crohn diseas induct remiss peopl crohn diseas mainten fistul crohn diseas side infliximab immunosuppress tnf class seriou potenti fatal infliximab carri fda blackbox warn label list side includ hypersensit allerg reaction risk reactiv tuberculosi serum sick risk multipl sclerosi seriou side includ lymphoma sever infect incldu progress multifoc leukoencephalopathi pml opportunist viral infect brain caus death adalimumab adalimumab market humira infliximab antibodi target tumour necrosi factor adalimumab ha reduc sign symptom approv treatment moder sever crohn diseas cd adult respond well convent treatment lost respons unabl toler infliximab adalimumab ha number seriou potenti fatal safeti concern characterist antitnf drug ha blackbox warn fda label list potenti side includ seriou sometim fatal blood disord seriou infect includ includ tb tuberculosi infect caus virus fungi bacteria rare report lymphoma solid tissu cancer rare report seriou liver injuri rare report demyelin central nervou system disord rare report cardiac failur natalizumab natalizumab market tysabri anti integrin monoclon antibodi ha util induct mainten treatment moder sever crohn diseas natalizumab appropri patient respond medic block tumor necrosi factoralpha infliximab januari fda approv natalizumab induct remiss mainten remiss moder sever crohn diseas total larg random control trial demonstr natalizumab increas rate remiss maintain symptomfre statu patient crohn diseas infliximab natalizumab ha link pml onli combin interferon label recommend monitor liver enzym conern possibl damag failur surgeri surgeri normal reserv complic crohn diseas diseas resist treatment drug confin locat remov surgeri manag complic crohn diseas includ fistula small bowel obstruct colon cancer small intestin cancer fibrostenot strictur strictureplasti expans strictur sometim perform otherwis complic resect anastomosi remov affect intestin rejoin healthi surgeri usual perform crohn diseas eg ileocolon resect type surgeri cure crohn diseas recurr reappear previous unaffect area intestin small intestin transplant experiment usual onli risk short bowel syndrom repeat resect surgeri diet lifestyl evid diet caus cure crohn diseas person crohn find food increas decreas symptom adjust diet accordingli food diari recommend posit neg food http wwwccfaorg fish oil ha reduc chanc relaps sever case peopl lactos intoler small bowel diseas benefit avoid lactos contain food mani diet instanc specif carbohydr diet propos treatment crohn diseas mani improv symptom proven actual cure crohn diseas thi diet usual adjust patient handl diet low residu diet reduc volum stool excret daili patient eat recommend total parenter nutrit tpn sourc vitamin nutrient http hopkinsgintsjhuedupageslatintemplatesindexcfm stress proven aggrav induc symptom crohn diseas http wwwccfaorgprintview pageurlinfoaboutcrohn suffer observ stress manag success method suppress ill bodi manag stress fit convers stress caus flare diseas thi day day life difficult smoke ha note associ crohn smoker crohn encourag quit becaus termin ileum common site involv site vitamin absorpt peopl crohn diseas risk defici supplement case extens small intestin involv fat solubl vitamin defici folat defici risk treat methotrex helminth therapi experiment idea call helminth therapi moder hookworm infect demonstr benefici host suffer diseas link overact immun system thi possibl explain hygien hypothesi helminth therapi help suffer crohn diseas hookworm therapi current trial stage univers nottingham unconvent natur thi therapi wide complementari altern medicin half crohn diseas suffer tri complementari altern therapi includ diet probiot fish oil herbal nutrit supplement benefit medic uncertain acupunctur acupunctur treat inflammatori bowel diseas china frequent western societi evid acupunctur ha benefit placebo improv qualiti life gener wellb small decreas bloodbound inflammatori marker medic methotrex folat antimetabolit drug chemotherapi mainten remiss longer corticosteroid metronidazol ciprofloxacin antibiot treat crohn colon perian involv thi ha approv food drug administr treatment complic includ abscess infect accompani crohn diseas thalidomid ha respons revers endoscop evid diseas cannabi treat crohn diseas antiinflammatori properti cannabi cannabisderiv drug help heal gut medic progress egg trichuri spp whipworm trichuri sui pig whipworm ha investig treatment crohn diseas mani clinic trial complet ongo therapi crohn diseas includ follow certolizumab pegyl fab fragment human anti tnf alpha monoclon antibodi wa efficaci placebo larg trial human anti monoclon antibodi develop abbott laboratori conjunct cambridg antibodi technolog treatment multipl autoimmun diseas includ crohn diseas phase ii trial complet promis result sargramostim granulocytemonocyt coloni stimul factor gmcsf ha substabti improv healthrel qualiti life pilot studi measur increas score ibd questionnair phase ii trial sargramostim significantli decreas cd sever compar placebo group improv qualiti life versu placebo trichuri sui pig whipworm studi improv crohn diseas symptom autolog stem cell transplant evalu rifabutin clarithromycin clofazimin antibiot design attack mycobacterium avium subsp paratuberculosi caus chron diseas thi treatment call myoconda test giaconda refer hanauer sb sandborn manag crohn diseas adult pdf gastroenterol doi pmid retriev hanauer sb strmberg oral pentasa treatment activ crohn diseas metaanalysi doubleblind placebocontrol trial clin gastroenterol hepatol pmid prantera cotton pallon al mesalamin treatment mild moder activ crohn ileiti result random multicent trial gastroenterolog pmid hanauer sb sulfasalazin vs steroid crohn diseas david goliath gastroenterolog pmid gopal latha senthil nachimuthu crohn diseas emedicin retriev greenberg gr feagan bg martin al oral budesonid activ crohn diseas canadian inflammatori bowel diseas studi group engl med pmid sandborn wj lfberg feagan bg hanauer sb campieri greenberg gr budesonid mainten remiss patient crohn diseas medic induc remiss predetermin pool analysi random doubleblind placebocontrol trial gastroenterol doi pmid steinhart feagan bg wong cj al combin budesonid antibiot therapi activ crohn diseas random control trial gastroenterolog pmid podolski daniel august inflammatori bowel diseas england journal medicin doi pmid retriev rosenberg jl levin wall aj kirsner jb control trial azathioprin crohn diseas dig di pmid dejaco harrer waldhoer miehsler vogelsang reinisch antibiot azathioprin treatment perian fistula crohn diseas aliment pharmacol ther pmid sandborn sutherland pearson modigliani prantera azathioprin induc remiss crohn diseas cochran databas syst rev pmid hanauer sb korelitz bi rutgeert al postop mainten crohn diseas remiss mesalamin placebo trial gastroenterolog pmid hanauer sb feagan bg lichtenstein gr al mainten infliximab crohn diseas accent randomis trial lancet pmid sand anderson fh bernstein cn chey wy feagan bg fedorak rn kamm ma korzenik jr lashner ba onken je rachmilewitz rutgeert wild wolf dc marster pa traver sb blank ma van devent sj infliximab mainten therapi fistul crohn diseas engl med feb pmid hanauer sb sandborn wj rutgeert al human antitumor necrosi factor monoclon antibodi adalimumab crohn diseas classici trial gastroenterolog quiz doi pmid rutgeert van assch vermeir review articl infliximab therapi inflammatori bowel diseas year aliment pharmacol ther doi pmid sandborn wj colombel jf enn al natalizumab induct mainten therapi crohn diseas engl med doi pmid medic guid humira pdf abbott laboratori retriev fda approv tysabri treat moderatetosever crohn diseas food drug administr retriev michetti mottet juillerat al sever steroidresist crohn diseas digest doi pmid feagan bg sandborn wj hass niecko white healthrel qualiti life dure natalizumab mainten therapi crohn diseas gastroenterol doi pmid ghosh goldin gordon malchow raskmadsen rutgeert vyhnlek zdorov palmer donoghu natalizumab activ crohn diseas engl med doi pmid langergould atla sw green aj bollen aw pelleti progress multifoc leukoencephalopathi patient treat natalizumab engl med doi pmid kleinschmidtdemast bk tyler kl progress multifoc leukoencephalopathi complic treatment natalizumab interferon multipl sclerosi engl med doi pmid hanauer stephen march inflammatori bowel diseas england journal medicin doi pmid retriev tysabri product inform sheet retriev belluzzi brignola campieri pera boschi miglioli june entericco fishoil prepar relaps crohn diseas abstract england journal medicin doi surgeri crohn diseas crohn coliti foundat america march retriev croes oneil masson cook melros pritchard spear proof concept studi establish necat americanu crohn patient reservoir donor british medic journal doi lay summari gottschal elain break viciou cycl intestin health diet baltimor kirkton press isbn feagan bg fedorak rn irvin ej al comparison methotrex placebo mainten remiss crohn diseas north american crohn studi group investig engl med pmid urs alm brni al compar studi metronidazol sulfasalazin activ crohn diseas cooper crohn diseas studi sweden ii result gastroenterolog pmid caprilli gassul escher al european evid base consensu diagnosi manag crohn diseas special situat gut suppl pmid joo brinkhau maluch al acupunctur moxibust treatment activ crohn diseas random control studi digest doi pmid schreiber rutgeert fedorak khaliqkareemi kamm boivin bernstein staun thomsen inn random placebocontrol trial certolizumab pegol treatment crohn disease gastroenterolog doi pmid mannon pj fuss ij mayer al antibodi activ crohn diseas engl med doi pmid cohen lb disappear crohn ulcer termin ileum thalidomid therapi gastroenterol gastroenterol author repli pmid cannabisbas drug offer hope inflammatori bowel diseas patient summer rw elliott de urban jf thompson weinstock jv trichuri sui therapi crohn diseas gut doi pmid oyama craig rm traynor ae al autolog hematopoiet stem cell transplant patient refractori crohn diseas gastroenterolog pmid korzenik jr dieckgraef bk valentin jf hausman df gilbert mj sargramostim activ crohn diseas engl med doi pmid dieckgraef improv mucos barrier function novel therapeut strategi crohn diseas topic relat crohn diseas main inflammatori bowel diseas biolog therapi inflammatori bowel diseas treatment crohn diseas crohn diseas activ relat term abdomin pain anal abscess erythema nodosum fistula granuloma ileum ileiti malabsorpt proctiti protein lose enteropathi pyoderma gangrenosum sacroili short bowel syndrom small bowel obstruct stenosi histori giovanni battista morgagni burril bernard crohn organ crohn coliti foundat america nation societi coliti crohn diseas peopl list peopl diagnos crohn diseas digest system digest diseas gastroenterolog primarili upper gi tract esophagu esophag candid ruptur boerhaav syndrom malloryweiss syndrom ue zenker diverticulum le barrett esophagu esophag motil disord nutcrack esophagu achalasia diffus esophag spasm gerd esophag strictur megaesophagu stomach gastriti atroph mntrier diseas gastroenter peptic gastric ulcer cush ulcer dieulafoy lesion dyspepsia pylor stenosi achlorhydria gastroparesi gastroptosi portal hypertens gastropathi gastric antral vascular ectasia gastric dump syndrom gastric volvulu intestin enteropathi small intestin duodenum jejunum ileum enter duoden jejun ileiti peptic duoden ulcer curl ulcer malabsorpt coeliac tropic sprue blind loop syndrom whippl short bowel syndrom steatorrhea larg intestin appendix colon append coliti pseudomembran ulcer ischem microscop collagen lymphocyt function colon diseas ib intestin pseudoobstruct ogilvi syndrom megacolon toxic megacolon diverticul diverticulosi larg andor small enterocol necrot ibd crohn diseas vascular abdomin angina mesenter ischemia angiodysplasia bowel obstruct ileu intussuscept volvulu fecal impact constip diarrhea rectum anu proctiti radiat proctiti proctalgia fugax rectal prolaps anal fissur anal fistula anal abscess accessori liver hepat viral hepat autoimmun hepat alcohol hepat cirrhosi pbc fatti liver nash vascular hepat venoocclus diseas portal hypertens nutmeg liver alcohol liver diseas liver failur hepat encephalopathi acut liver failur liver abscess hepatoren syndrom peliosi hepati gallbladd cholecyst gallston cholecystolithiasi cholesterolosi rokitanskyaschoff sinus postcholecystectomi syndrom bile duct other biliari tree cholang psc ascend cholestasi mirizzi syndrom biliari fistula haemobilia gallston cholelithiasi common bile duct choledocholithiasi biliari dyskinesia pancreat pancreat acut chronic hereditari pancreat pseudocyst exocrin pancreat insuffici pancreat fistula hernia diaphragmat congenit diaphragmat hiatu abdomin hernia inguin indirect direct umbil incision femor obtur hernia spigelian hernia periton periton spontan bacteri periton hemoperitoneum pneumoperitoneum gi bleed upper hematemesi melena lower hematochezia